Sunshine Biopharma Secures Patent for Coronavirus Treatment
Sunshine Biopharma announced that the United States Patent and Trademark Office has issued U.S. Patent No. 12,624,066 B2, titled "Compounds and Methods for Treatment of Coronavirus Infection." The newly granted patent protects Sunshine Biopharma's proprietary therapeutic compounds designed to inhibit coronavirus replication. The patent covers a series of small molecule inhibitors discovered and developed by Sunshine Biopharma scientists during the COVID-19 pandemic. These compounds target a critical viral enzyme responsible for suppression of the human immune system, making Coronavirus infections life-threatening.
